The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
    • Research Competitions
      • Research Competition Winners
    • Member discount codes
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Simon Goodman, PhD

Simon Goodman, PhD

Dr. Simon L. Goodman consults for the Antibody Society as Science and Technology program manager. ORCID: 0000-0002-3480-1346. He has spent most of his career working on molecules regulating cell-adhesion.

 

Dr. Goodman was with Merck KGaA in Darmstadt, Germany from 1993 to 2013, most recently leading the immunohistology group in the Translational and Biomarkers research section of Oncology preclinical pharmaceutical research, developing and validating antibodies for clinical biomarker analysis. Prior to that, as principal scientist, he was preclinical leader on the Cilengitide drug development team, where he supported the anti-adhesion drug through Phase 1, 2 and 3 trials, including presenting the drug to the NCI as an IND. This followed 15 years as head of a cell-biology laboratory in Merck, where he was involved in drug discovery.

Beside the clinical development candidates, his research at Merck on the integrin family of adhesion molecules developed technologies for bulk integrin production for drug screening. Collaboration with Prof. Amin Arnaout’s group in MGH, Cambridge, resulted in the watershed X-ray structures of integrin extracellular domains, both alone, in the presence of peptidic drug Cilengitide, the antibody-inhibitor Abituzumab, and bound to a fragment of extracellular matrix molecule fibronectin.

Before Merck, he studied cell adhesion processes at various Max-Planck institutes. Dr. Goodman was at the MPI for Biochemistry, Martinsried, discovering the primary cell adhesion site on laminin, at the MPI for rheumatology, in Erlangen, discovering integrin a7b1, and at the MPI Friedrich-Miescher laboratory in Tübingen, working on function-blocking antibodies.

He has published over 100 highly cited research papers (h-index: 62; i-index: 100. 16,400 citations. Source Google Scholar August 2019) and has some 100 patents granted or applied for. He was a leading witness in the “Research Safe-harbour” case, positively adjudicated in the US Supreme Court (545 U.S. 193; June 13th 2005).

In the UK Dr. Goodman worked at the Imperial Cancer Research Fund developing the colloidal gold system for immuno-scanning electron microscopy, and on cytokeratins. He graduated from the University of Sussex where he also gained his DPhil., in membrane biochemistry, in 1977. He is a Londoner.

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • The Antibody Society announces the election of new Directors and Officers January 26, 2023
  • AIRR Data Commons and iReceptor Science Gateway Start Major Collaboration with Type-1 Diabetes Researchers January 11, 2023
  • FDA approves Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease January 6, 2023

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals